Artal Group S.A. Cellectis S.A. Transaction History

Artal Group S.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2018 May 10, 2018	SELL	$27.78 - $35.19 $2.78 Million - $3.52 Million	-100,000 Closed	0 $0
Q3 2017 Nov 08, 2017	BUY	$21.65 - $32.18 $2.17 Million - $3.22 Million	100,000	100,000 $2.85 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $85.1M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.